Actively Recruiting
Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer
Led by Fujian Medical University · Updated on 2022-11-16
68
Participants Needed
1
Research Sites
304 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with resectable remnant gastric cancer were selected as study subjects to investigate the safety, efficacy, and feasibility of ICG near-infrared imaging tracing in guiding laparoscopic lymph node dissection for remnant gastric cancer by comparing injection ICG group and non-injection ICG group.
CONDITIONS
Official Title
Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age from 18 to 75 years
- Diagnosis of remnant gastric cancer (cT1-4a, N-/+, M0) confirmed by preoperative evaluation
- No distant metastasis and no direct invasion of pancreas, spleen, or other nearby organs
- Performance status of 0 or 1 on the ECOG scale
- ASA class I to III
- Written informed consent provided
You will not qualify if you...
- Women who are pregnant or breastfeeding
- Severe mental disorder
- History of previous upper abdominal surgery except laparoscopic cholecystectomy and gastrectomy
- History of previous gastric surgery including ESD/EMR for gastric cancer
- Refusal of laparoscopic resection
- Allergy to iodine agents
- Enlarged or bulky regional lymph nodes over 3cm by preoperative imaging
- History of other malignant diseases within the past five years
- Prior neoadjuvant chemotherapy or radiotherapy
- History of unstable angina or myocardial infarction within past six months
- Continuous systemic corticosteroid use within one month
- Requirement for simultaneous surgery for another disease
- Emergency surgery due to complications caused by gastric cancer
- Forced expiratory volume (FEV1) less than 50% of predicted values
- Linitis plastica or widespread disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fujian Medical University Union Hospital
Fuzhou, Fujian, China, 350000
Actively Recruiting
Research Team
H
Hualong Zheng
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here